drugset / Trial / NCT07808567
Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open master platform trial, which includes multi neo-adjuvant treatment trials, multi-center, national. This platform trial evaluates the major pathological response rate (mPR) after surgery. Intervention: The procedure consists of administering a neoadjuvant treatment and then performing pancreatic surgery. The POWER platform trial aims to study several neoadjuvant treatments prior to surgery. They will be described in each sub-study, in appendix. The surgery will be performed on one day and the end of the treatment is the safety visit post-surgery (90 days after surgery).
Timeline
- Start
- 2027-01
- Primary completion
- 2029-01
- Completion
- 2032-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Folfirinox | Unknown | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Nab-paclitaxel | Small molecule | — | — |